From November 1, 2022 to January 31, 2023, the company has repurchased 849,618 shares, representing 4.35% for $2.35 million. With this, the company has completed the repurchase of 3,725,114 shares, representing 18.21% for $10 million under the buyback announced on June 2, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.12 USD | 0.00% | -0.47% | -1.85% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-1.85% | 17.92M | |
+33.16% | 664B | |
+29.29% | 567B | |
-7.45% | 354B | |
+18.69% | 330B | |
+4.56% | 286B | |
+13.79% | 234B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.95% | 148B |
- Stock Market
- Equities
- PMCB Stock
- News PharmaCyte Biotech, Inc.
- Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on June 2, 2022.